Parkinson's Disease Trial, Recruiting NCT05402163 Sponsor: University of Toronto Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT05402163
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have Parkinson's disease and already have a deep brain stimulation (DBS) device implanted on both sides of the brain, using a Medtronic brand lead (wire)
  • You are able to give your consent to participate and are willing and able to follow the study's rules and schedule
  • Your current DBS battery needs to be replaced because it is running out of power
  • You have significant problems with walking, balance, and/or speech that meaningfully affect your daily life, as agreed upon by both you and the study doctor
  • There is evidence that your walking, balance, and/or speech problems are actually made worse by your DBS device — meaning these issues get better when the device is switched off
  • Your DBS device uses specific contact points (numbered 1 and/or 2 on one side of the brain, and/or 9 and/or 10 on the other side) (confirm with trial site)
  • Your brain produces a good enough electrical signal that can be picked up after the new device is fitted (confirm with trial site)

Who may not be able to join:

  • Your original DBS surgery used equipment from a brand other than Medtronic
  • Your treatment may require a stimulation setting that would not be compatible with the type of DBS used in this study (confirm with trial site)
  • You have another condition (such as a bone or joint problem) that could affect the study results
  • You currently have unstable or poorly controlled health problems
  • You have severe non-movement-related symptoms, such as significant depression or memory/thinking problems

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Toronto
Registry
ClinicalTrials.gov
Start date
1 June 2024
Est. completion
1 June 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in Activities of Daily Living using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II; Change in Quality of Life (QoL) using Parkinson's Disease Questionnaire (PDQ39); Change in Gait using the Zeno Walkway by Protokinetics; Change in Speech Quality using the Praat software (Phonetic Sciences)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov